![Per-Oluf Olsen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Per-Oluf Olsen
Directeur/Membre du Conseil chez
Nextera AS
Profil
Per-Oluf Olsen is currently the Director at Nextera AS and Co-Investor & External Partner at Birk Venture AS.
Previously, he was the Chief Executive Officer at Pronova BioPharma ASA from 2008 to 2009.
He also held positions as Principal at Rikshospitalet HF and Country Manager at Pfizer AS.
Mr. Olsen obtained an undergraduate degree from BI Norwegian Business School.
Postes actifs de Per-Oluf Olsen
| Sociétés | Poste | Début |
|---|---|---|
Birk Venture AS
 Birk Venture AS Investment ManagersFinance Birk Venture is an active manager which makes strategic, long-term investments in life science companies in the pharmaceutical, biotechnology, diagnostics, medical devices and instruments and consumer health sectors. Their geographic focus is on Scandinavia. The firm seeks to identify small-sized listed and unlisted start-up companies with the potential to be public within one to two years which have significant growth prospects, a unique technology and significant market potential. They prefer to invest in companies that have an attractive long-term business case, partnering with entrepreneurs and co-investors to fully exploit the market potential offered by the investee company's new technologies. Through board memberships or direct involvement in specific strategic projects, Birk Venture provides investee companies with a range of internal and external resources including management, sales & marketing, business development, licensing, intellectual property and product portfolio management. | Private Equity Investor | 01/03/2010 |
Nextera AS
 Nextera AS Miscellaneous Commercial ServicesCommercial Services Provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer | Directeur/Membre du Conseil | 01/01/2010 |
Anciens postes connus de Per-Oluf Olsen
| Sociétés | Poste | Fin |
|---|---|---|
Pronova BioPharma ASA
 Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets omega-3-derived pharmaceuticals | Directeur Général | 01/07/2009 |
Rikshospitalet HF
 Rikshospitalet HF Hospital/Nursing ManagementHealth Services Operates hospitals and healthcare centers | Corporate Officer/Principal | - |
Pfizer AS
 Pfizer AS Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops medicines | Corporate Officer/Principal | - |
Formation de Per-Oluf Olsen
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
5
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets omega-3-derived pharmaceuticals | Health Technology |
BI Norwegian Business School
 BI Norwegian Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rikshospitalet HF
Rikshospitalet HF Hospital/Nursing ManagementHealth Services Operates hospitals and healthcare centers | Health Services |
Nextera AS
Nextera AS Miscellaneous Commercial ServicesCommercial Services Provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer | Commercial Services |
Pfizer AS
Pfizer AS Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops medicines | Health Technology |
Birk Venture AS
Birk Venture AS Investment ManagersFinance Birk Venture is an active manager which makes strategic, long-term investments in life science companies in the pharmaceutical, biotechnology, diagnostics, medical devices and instruments and consumer health sectors. Their geographic focus is on Scandinavia. The firm seeks to identify small-sized listed and unlisted start-up companies with the potential to be public within one to two years which have significant growth prospects, a unique technology and significant market potential. They prefer to invest in companies that have an attractive long-term business case, partnering with entrepreneurs and co-investors to fully exploit the market potential offered by the investee company's new technologies. Through board memberships or direct involvement in specific strategic projects, Birk Venture provides investee companies with a range of internal and external resources including management, sales & marketing, business development, licensing, intellectual property and product portfolio management. | Finance |
